Research programme: antisense oligonucleotides VEGF - Idera Pharmaceuticals
Latest Information Update: 24 Aug 2007
At a glance
- Originator Idera Pharmaceuticals
- Mechanism of Action Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Sep 2005 Hybridon is now called Idera Pharmaceuticals
- 05 May 2005 Preclinical trials in Cancer in USA (unspecified route)